HUTCHMED (China) Balance Sheet Health

Financial Health criteria checks 5/6

HUTCHMED (China) has a total shareholder equity of $743.4M and total debt of $79.3M, which brings its debt-to-equity ratio to 10.7%. Its total assets and total liabilities are $1.3B and $536.4M respectively. HUTCHMED (China)'s EBIT is $18.4M making its interest coverage ratio -0.5. It has cash and short-term investments of $889.0M.

Key information

10.7%

Debt to equity ratio

US$79.34m

Debt

Interest coverage ratio	-0.5x
Cash	US$889.02m
Equity	US$743.39m
Total liabilities	US$536.39m
Total assets	US$1.28b

Recent financial health updates

Recent updates

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

Dec 18

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Nov 23

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Aug 24

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

May 10

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

Financial Position Analysis

Short Term Liabilities: HCM's short term assets ($1.1B) exceed its short term liabilities ($403.0M).

Long Term Liabilities: HCM's short term assets ($1.1B) exceed its long term liabilities ($133.4M).

Debt to Equity History and Analysis

Debt Level: HCM has more cash than its total debt.

Reducing Debt: HCM's debt to equity ratio has increased from 6.7% to 10.7% over the past 5 years.

Debt Coverage: HCM's debt is well covered by operating cash flow (276.3%).

Interest Coverage: HCM earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

HUTCHMED (China) Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

Recent updates

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Consensus EPS estimates upgraded to US$0.25 loss

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

CFO & Executive Director recently sold UK£2.4m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

Less than half of directors are independent

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

Now 21% undervalued after recent price drop

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Now 23% undervalued after recent price drop

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer

First half 2022 earnings released

HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED (China) Limited Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

HUTCHMED (China) Limited Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting